THIS SHARE WILL BE WORTH 3.00 IN 2009

Transco,
Agreed, not worried. Looking ahead.

Tipped in the Indie and the Times today.

Nice write ups. See links.http://news.independent.co.uk/business/analysis_and_features/article356310.ece

http://www.timesonline.co.uk/newspaper/0,,174-2122766,00.html

Geekman - Nice one - keep the faith......

For those that have read the Indie link, it states re CroFab 'Analysts believe it could be worth up to $8bn (4bn)'.
With royalty payments of 20%, that is 800,mil. If their predictions are correct, what price the sp then.

Nice pop today on press news - Unfortunately in my experience this normally
brings a pullback for those who knew it was comming. Expect it to come back to 84p min.
Not to worry though the fund managers wont be on the sidelines for much longer.

On low volume the closing sp was nicely up. The press reports did not tempt the punters. I wonder if Monday will show an L or OT trade for a large buy.

greekman and transco, thanks for the ongoing commentary which, to be honest, has influenced my decisions while adding to spread holdings. No pressure! My tree analysis on Protherics continues to give only one answer which seems to be a binary "buy" though yesterday was painful. Will continue to have a ridiculous weighting in this stock and add while it is under 1.

Suddenly a move at 1150 by all the mm's ( 9 ) that deal in this share. All moved on bid and ask. All this on low volume.
Why are they all suddenly competing with each other. Is something about to break.

Another nice move - news soon me thinks...

So it looks like Artimis Investment have increased their holdings according to my records. This is the last holding notification regarding Artimis.

The Company was informed by Artemis Investment Management Ltd. on 14 February 2005 that, following a sale of shares, Artemis Income no longer has a notifiable interest of shares in the Company.

Astrazeneca, are according to the weekend press looking for more tie-ups or licensing deals. They have even created a high level post, with sole responsibility to search for such deals. The main company mentioned in the article was the licensing deal with Protherics. Could they return looking for more. Even if not it was a nice little bit of publicity.

Re RNS
M&G Investment Management Limited , Prudential plc and certain of its subsidiary companies held a notifiable interest in 10,431,716. This is an increase from the 9,873,542 held on 25/01/06. Good to see the institutions increasing their holdings especially the way the stock market is lately.

Yes, it does show confidence in PTI which is especially engouraging bearing in mind the way the sp has stagnated of late.

Queen1,

Stagnation? - take a longer view chum. The chart is as positive a chart than i have seen this side on Christmas. Give it more time and the rewards will come.

It's moved sideways and down since I bought in "chum".

mmm so that was at most a month ago - come on be serious.
3 months view is a gamble - look 3 years ahead and you will make real money.

It was earlier than that but I'm in to make money so sitting tight.

Snakebite-serum firm on growth trail May 31 2006

David Williamson, Western Mail

SNAKEBITE serum manufacturer Protherics is preparing for global growth through a programme to help its managers identify weak links in their chain of command.

http://icwales.icnetwork.co.uk/0300business/0100news/tm_objectid=17150939&method=full&siteid=50082&headline=snakebite-serum-firm-on-growth-trail-name_page.html

Results as expected, and the next 2 to 3 year prospects look very good indeed.

Strong cash position at end of period of 25.4 million (2005: 7.3 million), following CytoFab(TM) upfront payment and equity contribution from AstraZeneca.

If you dig out the cash facts after all the ins and outs of R+D, acquisitions, investments etc, this paragraph reads well, and just about sums up the cash position.

Cash inflow from operating activities was 12.6 million compared to an outflow
of 2.8 million in the prior year. Although the operating loss for the year was
9.5 million, only 0.7 million of the initial 16.3 million non refundable
receipt from AstraZeneca was recognised as income in the period, and this is
reflected in the increased cash inflow from operations.

I think this may make the market sit up and take a bit more notice. There is a good indication in these results of things to come.

Well the market appears to like it, at 5.25p ( 6.35 ) up on a relatively good turnover of 1.93 million shares traded. This leads me to believe that institutional investment is about to increase.